CTOs on the Move

Black Diamond Therapeutics

www.blackdiamondtherapeutics.com

 
Black Diamond Therapeutics is a next-wave cancer precision medicine company. Black Diamond pioneered the development of selective medicines for patients with genetically defined cancers driven by oncogenes activated by allosteric mutations. Using its mutation, allostery, and pharmacology (MAP) computational and discovery platform, Black Diamond is uncovering new ways to functionally assess the mutational landscape of individual oncogenes – to discover and validate new targets and develop novel approaches to creating highly selective therapeutics. Black Diamond was founded by David M. Epstein, Ph.D., Elizabeth Buck, Ph.D., and Versant Ventures, and is the first new company to emerge from Versant`s Ridgeline Discovery ...
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Black Diamond Therapeutics raised $20M on 12/12/2018
Black Diamond Therapeutics raised $85M on 01/09/2019

Similar Companies

Galderma Canada

Galderma Canada Inc. is a Thornhill, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Frontier Derm Partners

Frontier Derm Partners is the premier dermatology clinic serving patients in Washington and Oregon

Triax Pharmaceuticals

Triax Pharmaceuticals is a Cranford, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Treace Medical Concepts

Treace Medical Concepts, Inc. brings revolutionary Hallux Valgus Surgery. A revolutionary approach to anatomic bunion correction. Call us today 904.373.5940.

XTuit

XTuit Pharmaceuticals, Inc. is a biopharmaceutical company developing novel microenvironment-activated therapeutics targeting key mechanisms resulting in hypoxia, decreased drug uptake, drug resistance, and decreased immune response. The Company’s proprietary drug development pipeline and integrated, sophisticated clinical biomarker platform will be used for accelerated clinical development across selected cancers and fibrotic disorders. XTuit’s compounds act through pleiotropic mechanisms to inhibit extracellular matrix synthesis and stabilization, and to silence activated stromal cells, including cancer-associated fibroblasts and stellate cells. As a result, XTuit compounds alleviate hypoxia and enable enhanced drug uptake through solid stress reduction. Moreover, the drugs have been shown to down-regulate stroma-induced tumor and inflammation signaling pathways to overcome treatment resistance. XTuit’s first two lead series are being developed for early clinical proof-of-concept in liver diseases and cancer.